18 Aug 2026 08:53:27 ET │ 14 pages CSL Ltd (CSL.AX) The worst seems past, base case mid single-digit mid-term NPAT growth CITI'S TAKE CSL's FY27 NPAT guide was ahead of VA consensus (5% growth vs 1-2% growth CC) but generated a strong stock price reaction (+17%). Our new PT is AUD160 (from AUD110) which is mainly a product of rolling our DCF valuation and adjusting the peer PE multiple we apply from 9x to 14x for our blended valuation method, as global therapeutics names have seen more of a bid recently. He ...